Focused light injures skin so it rebuilds with newer connective tissue, most reliably reducing facial lines, evening color, smoothing texture and improving sunken acne marks. Deeper full-surface treatment changes the most but needs longer recovery. Redness, swelling and peeling always follow; darker skin risks temporary darkening; the deepest treatments risk permanent lightening or scarring. Evidence remains thin. (Full Review)

Protocol

Ablative Fractional (Mainstream)

1–3 sessions

Fractional CO₂/erbium, 10–30 mJ/microbeam, 5–25% coverage, 4–8 weeks apart

Non-Ablative Fractional

4–6 sessions

1550 nm fiber or 1927 nm thulium, 2–4 week intervals; standard for phototypes IV–VI

Full-Field Ablative CO₂

Single treatment

10,600 nm, 250–350 mJ/pulse, 2–3 passes; largest change, longest recovery

Time to effect

Wrinkles & Collagen

3–6 months

Dermal remodeling accrues; not fully assessable before then

Texture & Pigment

7–14 days

After re-epithelialization; 3–7 days for non-ablative

Result Durability

5–10 yrs / 1–3 yrs

Full-field ablative vs fractional

Benefits

High: Reduction of facial wrinkles and fine lines; improvement of photodamage-related dyspigmentation and skin texture; improvement of atrophic acne scars

Medium: Dermal collagen remodeling and increased dermal thickness; clearance of actinic keratoses and precancerous field damage; enhanced delivery of topical actives

Low: Skin tightening and laxity improvement; improvement of photoaged skin on the hands, neck and chest

Speculative: Long-term reduction in keratinocyte carcinoma incidence; reduction of local senescent cell burden

Contraindications

Active herpes labialis or bacterial infection in the field

Isotretinoin exposure within six months (ablative)

Prior radiotherapy to the treatment field

Active connective tissue disease with cutaneous involvement (systemic sclerosis, cutaneous lupus)

History of keloid formation

Pregnancy and lactation

Full-field ablative in Fitzpatrick phototypes IV–VI

Unrealistic expectations of correcting volume-loss laxity

Key Interactions

Anticoagulants and antiplatelet agents (warfarin, apixaban, rivaroxaban, clopidogrel, aspirin)

Over-the-counter analgesics and antiplatelet agents (aspirin, ibuprofen, naproxen, diclofenac gel)

Over-the-counter topical actives (retinol, alpha- and beta-hydroxy acid exfoliants, benzoyl peroxide, hydroquinone, scrubs)

Photosensitizing medications (doxycycline, minocycline, ciprofloxacin, hydrochlorothiazide, amiodarone, voriconazole)

Immunosuppressants (prednisone, tacrolimus, mycophenolate, methotrexate, TNF inhibitors)

Supplements with antiplatelet or anticoagulant effects (fish oil, vitamin E, Ginkgo, garlic, ginger, ginseng, nattokinase, curcumin)

Photosensitizing supplements (St. John's wort, bergamot, Ammi majus, Angelica)

Other cosmetic interventions (botulinum toxin, fillers, peels, microneedling, radiofrequency)

Risk & Side Effects

High: Post-procedure erythema; post-inflammatory hyperpigmentation; procedural pain and discomfort; oedema, crusting and functional downtime

Medium: Delayed permanent hypopigmentation; infection and herpes simplex reactivation; hypertrophic scarring; acneiform eruption and milia

Low: Ectropion and periorbital complications; allergic and irritant contact dermatitis; prolonged photosensitivity and rebound pigmentation

Speculative: Cumulative dermal atrophy from repeated aggressive treatment; koebnerization of latent inflammatory skin disease

Monitoring

Marker	Target	Why
Hemoglobin A1c	4.8–5.4%	Glycemic control predicts re-epithelialization speed
Fasting glucose	75–86 mg/dL	Confirms current glycemic state alongside the 3-month average
Serum albumin	4.2–5.0 g/dL	Marks protein availability for collagen matrix synthesis
Ferritin	50–150 ng/mL (women), 50–200 ng/mL (men)	Iron is a cofactor for the enzymes that stabilise collagen
25-hydroxyvitamin D	40–60 ng/mL	Supports keratinocyte differentiation and barrier recovery
High-sensitivity C-reactive protein	<0.5 mg/L	Pro-inflammatory baseline predicts prolonged post-procedure erythema
Serum zinc	90–120 µg/dL	Required for epithelial proliferation and wound closure
Complete blood count with differential	Hemoglobin 13.5–15.0 g/dL (women), 14.5–16.5 g/dL (men)	Oxygen delivery to the healing field; screens for occult infection risk
Herpes simplex virus type 1 and 2 IgG antibodies	Negative preferred; positive is not a contraindication	Identifies latent infection that resurfacing can reactivate
Plasma ascorbate (vitamin C)	0.8–1.5 mg/dL	Rate-limiting cofactor for collagen cross-linking

Cadence: Baseline assessment; wound review at day 3 and day 7–10; pigmentary assessment at week 4 and week 8; outcome photography at month 3 and month 6; annual review thereafter

Qualitative Assessment

Standardised photography under fixed lighting at baseline, month 3 and month 6
Fitzpatrick wrinkle severity and Glogau photoaging class scored by the same assessor
Time to complete re-epithelialization relative to the expected 10–21 days
Trajectory of erythema resolution week by week
Onset of pigmentary change at weeks 4–8
Self-assessed skin texture, makeup requirement and confidence in appearance
Sleep quality and daily function during the recovery period

Laser Resurfacing for Skin Rejuvenation

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment